You searched for "presentation"

682 results found

Neuroendocrine bladder tumour

A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

Current developments and innovations of the WASHOUT study: A large-scale observational study of inpatient haematuria

Unscheduled haematuria admissions ranks among the most common urological emergencies, yet its investigation and management still lack standardisation. The readmission rate for haematuria is substantial, with reports as high as 8%, and the median hospital stay for such cases in...

New techniques in UTI diagnosis

Urinary tract infection (UTI) is a common reason for seeking medical care in both primary and secondary settings. Half of women will have at least one episode of cystitis in their lifetime, and a third of them will have experienced...

HIV / AIDS – implications for the urologist

“It’s no fun to have HIV even though it’s viewed as a chronic, controllable disease. It means being wedded to the health system.” - Philip Berger, Associate Professor in the Department of Family and Community Medicine, Toronto, Canada; and leading...

Peyronie’s disease: a review and update

Peyronie’s disease (PD) describes an acquired disease of the penis, which is characterised by a number of signs and symptoms. These include penile pain, curvature, palpable plaques, wasting or narrowing of the penile shaft, a hinge deformity and potentially catastrophic...

Clear cell urothelial carcinoma: a highly aggressive morphological variant in the bladder and upper urinary tract

Clear cell urothelial carcinoma (CCUC) is a rare morphological variant of transitional cell carcinoma (TCC). It can occur anywhere along the urothelial tract and is characterised histologically by high grade carcinoma with an abundance of clear, glycogen-rich cytoplasm [1]. Alternative...

Neurourology

Case 1 What are the urological indications for use of this medication? What is the mechanism of action when used in the bladder? What is the average duration of action? What are the contraindications to the use of this medication?...

A ‘survival guide’ to an ST3 year in urology

Following success in national selection, it soon dawns on the successful candidate that entry into higher surgical training (HST) requires more than a little clinical knowledge. The role requires administrative and organisational skills not hitherto called upon. This additional skill...

In conversation with Sarika Nalagatla

We were delighted to catch up with Sarika Nalagatla, new Chair of the BAUS Section of Trainees (BSoT) about her life as a trainee urologist and plans for the association. Can you tell us a little bit about what led...

Urology Podcasts and NotebookLM

Podcasts, downloadable or streamable digital audio / video shows, have surged in popularity over the last five years due to the ubiquity of smartphones, high-speed mobile networks, and accessible content creation technology. They offer on-the-go access to expert discussions, clinical...

Focal therapy for prostate cancer – ready for prime time?

The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...

EAU (European Association of Urology) Talent Incubator Programme: Policy & Innovation

The randomised controlled trial (RCT) will remain one of the most important methods for medical advancements. A solid framework, an extensive network and financial resources are key factors in the success of a trial. In this module of the Talent Incubator Programme, we will address the practical side of conducting research and trials with support from policy experts, industry representatives and patient advocates